X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Life Sciences Companies divorce agrochem operations - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Jul 14, 2000

    Life Sciences Companies divorce agrochem operations

    The wheel seems to have come a full circle for life science companies. The last year has seen an across the board spin off of their agro–chemical arms by the life science (a euphemism for a conglomerate of pharmaceutical and agrochemical operations) corporations.

    Novartis (formed with the merger of Ciba and Sandoz) de–merged its agro chemical arm and proposed a merger with Zeneca (the agro–chemical arm of Astra–Zeneca) to form Syngenta. Aventis Crop Science came into being with the merger of the agro–chemical arms of Hoechst Marion Roussel and Rhone Poulenc. Then American Home Products announced the sale of its agro–chemical business Cyanamid to the German specialty chemical conglomerate BASF.

    Why has this happened? Why have international pharmaceutical majors gone back to the core competence mantra? Till the last year it was the pharmaceutical operations of the life science corporations, which were supposed to finance the biotech revolution. What has changed?

    The answers were provided by Mr. Edward Schillinger, Managing Director, Novartis India at last week’s analysts meet. He said that there were two reasons for these developments. First, was the realisation, among life science companies, that there were hardly any synergies between the pharmaceutical operations and the agrochemical operations of the life science companies. The two catered to totally different markets and the type of personnel running the two operations were different. It was equivalent to running two businesses under the aegis of one company.

    The second reason for the hive off was the pressure from the shareholders. This was due to the fact that last year was a bad year for the agrochemical business. (Even otherwise the returns from the pharmaceutical business are relatively higher than the agrochemical business.) Hence it was imperative that the shareholders interested in the pharmaceutical business were not deprived of their returns, which were otherwise getting averaged out by the lower returns from the agrochemical operations.

    This would however imply that agro–chemical firms will have to fund their forays into biotech, gentology and tissue culture on their own. Mr. Schillinger, however clarified that the agrochemical businesses were not unviable businesses. These were sound businesses, which could very well finance their ambitious plans.

    Infact, after the recent round of restructuring there would be around five firms, the world over which would dominate the agrochemical business. These include Monsanto (which ironically has proposed a merger with pharma major Pharmacia & Upjohn), Aventis Crop Science, Syngenta, Bayer and BASF–Cyanamid.

     

     

    Equitymaster requests your view! Post a comment on "Life Sciences Companies divorce agrochem operations". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    The Power of 5 Minutes (The 5 Minute Wrapup)

    Jun 16, 2017

    Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    S&P BSE HEALTHCARE


    Aug 18, 2017 (Close)

    S&P BSE HEALTHCARE 5-YR ANALYSIS

    COMPARE COMPANY

    MARKET STATS